An administrative law judge has ruled in favor of Illumina in its $7.1 billion acquisition of cancer-testing developer Grail Inc., dealing a defeat to the Federal Trade Commission’s efforts to unwind the deal on antitrust grounds, the company said.

Illumina said the judge rejected the FTC’s position that the deal would hurt competition in the market for multicancer early-detection tests.